Why the study?
Do enalapril, BQ-123, and bosentan reduce arterial pressure and total peripheral resistance in dogs with chronic myocardial infarction?
Do enalapril, BQ-123, and bosentan reduce arterial pressure and total peripheral resistance in dogs with chronic myocardial infarction?
In a canine model of chronic MI, endothelin antagonists and ACE inhibitors reduce arterial pressure and peripheral resistance, indicating both systems maintain cardiovascular function.
Supports hemodynamic effects of ACE/endothelin blockade in canine chronic MI; leaves open clinical translation.
The hemodynamic effects of enalapril, an angiotensin-converting enzyme inhibitor, BQ-123, a selective ETA receptor antagonist, and bosentan, a nonselective ETA and ETB receptor antagonist, were studied in dogs 4 weeks after myocardial infarction (MI) produced by ligation of the left anterior descending coronary artery. Reduced arterial pressure and total peripheral resistance after administration of analapril, BQ-123, and bosentan revealed that both the renin-angiotensin system and endothelin participate in maintenance of cardiovascular function in chronic MI.
No takes yet. Share an insight, caveat, or question.
Ohta et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: